{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-001156","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.427621+00:00","generated_at":"2026-05-28T11:29:40.096701+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CERo Therapeutics to effect 1-for-100 reverse stock split to cure Nasdaq bid price deficiency","bullets":["Reverse stock split at 1-for-100 ratio effective Jan 8, 2025; reduces outstanding shares from ~260M to ~2.6M.","Company received Nasdaq delisting notice on Oct 24, 2024 after bid price ≤$0.10 for ten consecutive days.","Company presented compliance plan to Nasdaq on Dec 17, 2024; believes reverse split will cure deficiency.","No fractional shares issued; stockholders entitled to fractional shares will round up to whole share."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-001156","json":"https://secwatch.observer/filing/0001213900-25-001156.json","markdown":"https://secwatch.observer/filing/0001213900-25-001156.md","text":"https://secwatch.observer/filing/0001213900-25-001156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/0001213900-25-001156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/ea0226772-8k_cerotherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T11:29:40.096701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d653982e8fabae094561a163c06f05c06f30d20","claim":"CERO THERAPEUTICS HOLDINGS, INC.: Amended certificate of incorporation to effect a 1-for-100 reverse stock split (effective 2025-01-08).","evidence_excerpt":"On January 6, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/0001213900-25-001156-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-01-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}